The HTA is announcing rules for bone and skin products to protect patients from diseases such as HIV, Hepatitis C and CJD.
The rules will apply to material from humans that does not contain cells.
They mainly apply to two types of acellular product: products from bone used in orthopaedic surgery, such as hip or knee operations, or dentistry, and products from skin used to promote wound healing after injury or burns.
The rules will only affect companies who import or store acellular products prior to distribution to end users.
Companies must apply to the HTA for a licence by 6 April 2009, though earlier applications are welcomed.
The HTA policy on acellular material has been revised in the light of adverse events in other parts of Europe and on the advice of the European Commission.
Dr Sandy Mather, director of regulation at the Human Tissue Authority, said: 'Although the risk of transmitting disease through acellular healthcare products is very small, the diseases that could be transmitted are very serious and include HIV and CJD.
'This regulation will give us the opportunity to ensure that we can trace the person that the products came from, that products have been rigorously tested before use and that we can easily recall any products that have a risk attached.'
